Oncogenic YAP mediates changes in chromatin accessibility and activity that drive cell cycle gene expression and cell migration

• Published in: Nucleic acids research Vol. 51; no. 9; pp. 4266 - 4283
• Main Authors: Fetiva, Maria Camila, Liss, Franziska, Gertzmann, Dörthe, Thomas, Julius, Gantert, Benedikt, Vogl, Magdalena, Sira, Nataliia, Weinstock, Grit, Kneitz, Susanne, Ade, Carsten P, Gaubatz, Stefan
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 22.05.2023
• Subjects: Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell Line; Cell Movement - genetics; Chromatin - genetics; Chromatin - metabolism; DNA Polymerase II - chemistry; DNA Polymerase II - metabolism; Enhancer Elements, Genetic; Gene regulation, Chromatin and Epigenetics; Genes, cdc - genetics; Humans; Phosphoproteins - genetics; Phosphoproteins - metabolism; Phosphorylation; Transcription Factors - metabolism; Transcription, Genetic; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism; YAP-Signaling Proteins - chemistry; YAP-Signaling Proteins - metabolism
• ISSN: 0305-1048; 1362-4962
• DOI: 10.1093/nar/gkad107

Abstract YAP, the key protein effector of the Hippo pathway, is a transcriptional co-activator that controls the expression of cell cycle genes, promotes cell growth and proliferation and regulates organ size. YAP modulates gene transcription by binding to distal enhancers, but the mechanisms of gene regulation by YAP-bound enhancers remain poorly understood. Here we show that constitutive active YAP5SA leads to widespread changes in chromatin accessibility in untransformed MCF10A cells. Newly accessible regions include YAP-bound enhancers that mediate activation of cycle genes regulated by the Myb-MuvB (MMB) complex. By CRISPR-interference we identify a role for YAP-bound enhancers in phosphorylation of Pol II at Ser5 at MMB-regulated promoters, extending previously published studies that suggested YAP primarily regulates the pause-release step and transcriptional elongation. YAP5SA also leads to less accessible ‘closed’ chromatin regions, which are not directly YAP-bound but which contain binding motifs for the p53 family of transcription factors. Diminished accessibility at these regions is, at least in part, a consequence of reduced expression and chromatin-binding of the p53 family member ΔNp63 resulting in downregulation of ΔNp63-target genes and promoting YAP-mediated cell migration. In summary, our studies uncover changes in chromatin accessibility and activity that contribute to the oncogenic activities of YAP.